The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
Open accessAbstract
Purpose: Panitumumab, a fully human antibody targeting the epidermal growth factor receptor, is active in patients with metastatic colorectal cancer (mCRC). This trial evaluated panitumumab added to bevacizumab and chemotherapy (oxaliplatin- and irinotecan-based) as first-line treatment for mCRC. Patients and Methods: Patients were randomly assigned within each chemotherapy cohort to bevacizumab and chemotherapy with or without panitumumab 6 mg/kg every 2 weeks. The primary end point was progression-free survival (PFS) within the oxaliplatin cohort. Tumor assessments were performed every 12 weeks and reviewed centrally. Results: A total of 823 and 230 patients were randomly assigned to the oxaliplatin and irinotecan cohorts, respectively. Panitumumab was discontinued after a planned interim analysis of 812 oxaliplatin patients showed worse efficacy in the panitumumab arm. In the final analysis, median PFS was 10.0 and 11.4 months for the panitumumab and control arms, respectively (HR, 1.27; 95% CI, 1.06 to 1.52); median survival was 19.4 months and 24.5 months for the panitumumab and control arms, respectively. Grade 3/4 adverse events in the oxaliplatin cohort (panitumumab v control) included skin toxicity (36% v 1%), diarrhea (24% v 13%), infections (19% v 10%), and pulmonary embolism (6% v 4%). Increased toxicity without evidence of improved efficacy was observed in the panitumumab arm of the irinotecan cohort. KRAS analyses showed adverse outcomes for the panitumumab arm in both wild-type and mutant groups. Conclusion: The addition of panitumumab to bevacizumab and oxaliplatin- or irinotecan-based chemotherapy results in increased toxicity and decreased PFS. These combinations are not recommended for the treatment of mCRC in clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The PACCE study evaluated the addition of panitumumab to chemotherapy and bevacizumab, showing that the combined use of two biological agents may result in adverse outcomes irrespective of RAS mutation status [19].”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
Self-citationVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
Cetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Research works printed but not linked: 3
- Mitchell EP, 10th Annual World Congress of Gastrointestinal Cancers
- Van Cutsem E, 2007, J Clin Oncol, 25, 18s
- Ciardiello F, 2000, Clin Cancer Res, 6, 3739
Cited by
Sorted by citations
Items 601–700 of 849
Bevacizumab Plus Chemotherapy in Metastatic Colorectal Cancer Patients Treated in Clinical Practice
Rossi, L., Veltri, E. M., Zullo, A., Zoratto, F., Colonna, M., Seri, M. D., Longo, F., Mottolese, M., Giannarelli, D., Ruco, L., et al. (2012) · Future Oncology · doi:10.2217/fon.12.108 · Cited by 5
Antiepidermal Growth Factor Receptor Monoclonal Antibodies: Applications in Colorectal Cancer
Azizi, E., Kittai, A. S., & Kozuch, P. S. (2012) · Chemotherapy Research and Practice · doi:10.1155/2012/198197 · Cited by 4
New approaches and targets in advanced colorectal cancer
Macarulla, T. M., Capdevila, J., Pérez-García, J. M., Ramos, F. J., Élez, E., Markman, B., Ruiz-Echarri, M., & Tabernero, J. M. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70019-x · Cited by 4
Emiloju, O. E., Zhu, M., Xie, H., Jin, Z., Sinicrope, F. A., & Hubbard, J. M. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01142-8 · Cited by 4
Dong, Y., Santol, J., Gruenberger, B., Lenauer, A., Laengle, F., Thaler, J., Piringer, G., Eisterer, W., Djanani, A. M., Stift, J., et al. (2024) · Cancers · doi:10.3390/cancers16050857 · Cited by 4
Guo, H., Miao, L., & Yu, C. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177219 · Cited by 4
Trastuzumab-Resistance and Breast Cancer
Dokmanovic, M., & Jin, W. (2011) · InTech eBooks · doi:10.5772/20936 · Cited by 4
Carlomagno, C., Daniele, G., Bianco, R., Marciano, R., Damiano, V., Matano, E., Nappi, L., Pepe, S., Placido, S. D., & Tortora, G. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.218 · Cited by 4
Landsman-Blumberg, P. B., Carter, G. C., Johnson, B. H., Sedgley, R., Nicol, S. J., Li, L., & Shankaran, V. (2014) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.05.001 · Cited by 4
Long-Term Treatment of Metastatic Colorectal Cancer with Panitumumab
López-Gómez, M., Merino, M. J., & Casado, E. (2012) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s5055 · Cited by 5
How to integrate biologicals in the continuum of care
Venugopal, B., & Cassidy, J. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70017-6 · Cited by 4
Maintenance therapy for metastatic colorectal cancer
Ciardiello, F. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00308-3 · Cited by 4
Comparative and combined effectiveness of innovative therapies in cancer: a literature review
Geldof, T., Rawal, S., Dyck, W. V., & Huys, I. (2019) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2018-0131 · Cited by 5
ten Hoorn, S., Mol, L., Sommeijer, D. W., Nijman, L. E., van den Bosch, T., de Back, T. R., Ylstra, B., van Dijk, E., van Noesel, C. J. M., Reinten, R. J. A., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.11.006 · Cited by 4
Wan, Y., & Luo, D. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-39 · Cited by 4
da Silva, W. C., Godman, B., Acúrcio, F. D. A., Cherchiglia, M. L., Martin, A. P., Maruszczyk, K., Izidoro, J. B., Portella, M. A. M., Lana, A. P., Neto, O. H. C., et al. (2021) · Applied Health Economics and Health Policy · doi:10.1007/s40258-020-00626-0 · Cited by 4
Safety and Efficacy of Panitumumab in the Treatment of Metastatic Colorectal Cancer
Freeman, D. J. (2009) · Clinical Medicine Therapeutics · doi:10.4137/cmt.s2039 · Cited by 4
EGFR/HER1 : histoire d’une cible thérapeutique
Viel, E., Curtit, E., Mansi, L., & Vignot, S. (2012) · Bulletin du Cancer · doi:10.1684/bdc.2011.1385 · Cited by 4
Rihawi, K., Giampieri, R., Scartozzi, M., Pusceddu, V., Bonotto, M., Fasola, G., Cascinu, S., & Aprile, G. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1054479 · Cited by 4
Shitara, K., Yokota, T., Takahari, D., Shibata, T., Sato, Y., Tajika, M., Ura, T., & Muro, K. (2010) · Case Reports in Oncology · doi:10.1159/000319474 · Cited by 4
Monoclonal Antibodies in Solid Tumours
Markman, B., & Tabernero, J. M. (2010) · Current Clinical Pharmacology · doi:10.2174/157488410791498833 · Cited by 4
Köhne, C., Vanhoefer, U. J., & Hartung, G. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70015-2 · Cited by 4
What can molecular pathology offer for optimal decision making?
Aust, D. E., Sommer, U., & Baretton, G. B. (2012) · Annals of Oncology · doi:10.1093/annonc/mds346 · Cited by 4
Independent Radiologic Review in Metastatic Colorectal Cancer: Systematic Review and Meta-Analysis
Lima, J. P. D. S. N., Souza, F. H., de Andrade, D. A. P., Carvalheira, J. B. C., & dos Santos, L. V. (2012) · Radiology · doi:10.1148/radiol.11111111 · Cited by 4
Multidisciplinary Management of Early-Stage Rectal Cancer
Phillips, J. G., Hong, T. S., & Ryan, D. P. (2012) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2012.0160 · Cited by 4
Precision Medicine in Gastrointestinal Pathology
Wang, D. H., & Park, J. Y. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0317-ra · Cited by 4
Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer.
Goldberg, R. M., Meropol, N. J., & Tabernero, J. M. (2009) · PubMed Central · Cited by 4
Goey, K. K. H., Mahmoud, R., Sørbye, H., Glimelius, B. L. G., Köhne, C.-H., Sargent, D. J., Punt, C. J. A., van Oijen, M. G. H., & Koopman, M. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.026 · Cited by 4
Chen, J., Wang, J., Ni, T., He, H., & Zheng, Q. (2020) · Medicine · doi:10.1097/md.0000000000019908 · Cited by 4
Yao, Y., Liu, Z., Zhang, H., Li, J., Peng, Z., Yu, J., Cao, B., & Shen, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.754858 · Cited by 6
Diarrhea, Constipation, and Obstruction in Cancer Management
Anthony, L. B. (2010) · Springer eBooks · doi:10.1007/978-1-4419-1225-1_26 · Cited by 4
Advancements in Large Language Models ( LLMs ): Empowering Drug Discovery
Song, B., Li, X., Chao, X., Wang, L. S., Liu, Y., Xia, Z., Cao, D., & Fu, X. (2025) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.70054 · Cited by 5
Single-cell systems analysis: decision geometry in outliers
Abrahams, L. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btaa1078 · Cited by 3
Bergsland, E. K. (2014) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2014.09.002 · Cited by 3
Banerjee, S. N., & Cunningham, D. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.s.004 · Cited by 3
Metastatic Colorectal Cancer: Focus on Panitumumab
Jimeno, S. L. D. A. A. (2010) · Clinical Medicine Reviews in Oncology · doi:10.4137/cmro.s1657 · Cited by 3
Yang, M., & Yeatman, T. J. (2017) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2017.1362316 · Cited by 3
Urban, H., Maurer, G. D., Luger, A., Lorenz, N. I., Sauer, B., Stroh, C., Trojan, J., Mittelbronn, M. G. A., Steinbach, J., Harter, P. N., et al. (2020) · Cancers · doi:10.3390/cancers12103050 · Cited by 3
Systemic Treatment: Maintenance Compared with Holiday
Punt, C. J. A., Simkens, L. H. J., & Koopman, M. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.85 · Cited by 3
Giuliani, J., & Bonetti, A. V. (2016) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-016-9862-0 · Cited by 3
Lin, F., Li, H., Wang, J., & Wang, F. (2018) · Bioscience Reports · doi:10.1042/bsr20180641 · Cited by 3
Liver transplantation for metastatic colorectal cancer (case report)
Поршенников, И. А., Sokolov, A. V., Shchekina, E. E., Chubukov, A. Y., Tret'yakova, T. A., Ostanina, I. B., Kartashov, A. S., Korobeynikova, M., Yushina, E., & Bykov, A. Y. (2019) · Annaly khirurgicheskoy gepatologii = Annals of HPB surgery · doi:10.16931/1995-5464.2018454-67 · Cited by 3
Sequencing of Treatment in Advanced Unresectable Colorectal Cancer
Grem, J. L. (2013) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2013.0218 · Cited by 3
Chemotherapy: Metastatic Disease
Field, K. M., & Zalcberg, J. R. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-567-5_12 · Cited by 3
Biologic Agents in the Treatment of Colorectal Cancer: The Last Decade; the Lost Decade?
Venook, A. P., & Saltz, L. B. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e121 · Cited by 3
Tang, N., Li, H., Qiu, Y.-L., Zhou, G., Wang, Y., Ma, J., Chang, Y., & Mei, Q. (2014) · Tumor Biology · doi:10.1007/s13277-014-2354-6 · Cited by 3
Loupakis, F., Cremolini, C., Schirripa, M., Masi, G., & Falcone, A. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552882 · Cited by 3
A new design immunotoxin for killing high-grade glioma U87 cells: Fromin vitrotoin vivo
Luqiu, Z., Yiquan, K., Gengqiang, L., Liu, Y., Xiaodan, J., & Yingqian, C. (2012) · Journal of Immunotoxicology · doi:10.3109/1547691x.2012.661487 · Cited by 3
Clary, B. M., Grothey, A. A., Kopetz, S., & Marsh, R. (2013) · HPB · doi:10.1111/j.1477-2574.2012.00598.x · Cited by 3
Where now for anti-EGF receptor therapies in colorectal cancer?
Shaw, P. H., & Adams, R. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.143 · Cited by 3
Systemic Therapy for Colon Cancer
El‐Shami, K., Nallapareddy, S., & Messersmith, W. A. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-4686-8.50020-8 · Cited by 3
Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer
Larsen, F. O., Markussen, A., Nielsen, D. L., Colville‐Ebeling, B., Riis, L. B., & Jensen, B. V. (2017) · Oncology · doi:10.1159/000475818 · Cited by 3
Adenocarcinoma of the Colon and Rectum
Tan, W. J., & Weiser, M. R. (2019) · DeckerMed Surgery · doi:10.2310/surg.2073 · Cited by 3
Therapeutic Antibodies in Cancer Therapy
Gasser, M., & Waaga-Gasser, A. M. (2015) · Springer eBooks · doi:10.1007/978-3-319-22473-2_6 · Cited by 3
Diarrhea, Constipation, and Obstruction in Cancer Management
Anthony, L. B., & Chauhan, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-90990-5_28 · Cited by 3
Bispecific Antibodies and Immune Therapy Targeting
Kiprijanov, S. M. (2011) · Wiley eBooks · doi:10.1002/9783527634057.ch16 · Cited by 3
Cetuximab or Bevacizumab With First-Line Chemotherapy in Advanced KRAS Wild-Type Colorectal Cancer
Lieu, C. H., & Messersmith, W. A. (2017) · JAMA · doi:10.1001/jama.2017.6673 · Cited by 3
Hong, Y., Zhao, Q., & Wang, J. (2025) · Bioinformatics · doi:10.1093/bioinformatics/btaf326 · Cited by 2
Oedingen, C., MacDonald, K. V., Stein, B. D., Batist, G., Cheung, W. Y., Gill, S., Goldenberg, B. A., Ko, Y., Marshall, D. A., & The Colorectal Cancer Canada’s Patient Values Project (2025) · Patient · doi:10.1007/s40271-025-00760-8 · Cited by 2
Treatment Paradigms With Epidermal Growth Factor Receptor–Targeted Therapies in Colorectal Cancer
Stein, S., Cohen, D. J., & Höchster, H. S. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.s.006 · Cited by 2
Burtness, B. A. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182326944 · Cited by 2
Nakatsumi, H., Komatsu, Y., Harada, K., Kawamoto, Y., Yuki, S., Sawada, K., Ishiguro, A., Sogabe, S., Ando, T., Sasaki, Y., et al. (2024) · International Journal of Cancer · doi:10.1002/ijc.35116 · Cited by 2
Keshavarzi, F., Salari, N., Jambarsang, S., Tabatabaei, S. M., Shahsavari, S., & Fournier, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36464 · Cited by 2
Gastrointestinal Malignancy: Genetic Implications to Clinical Applications
Trembath, H. E., Yeh, J. J., & Lopez, N. (2024) · Cancer treatment and research · doi:10.1007/978-3-031-61238-1_15 · Cited by 3
Frontline Strategies for Metastatic Colorectal Cancer: New Sides to the Story
King, G. T. (2017) · American Journal of Hematology / Oncology® · Cited by 2
Distinct Pathologic Roles for Glycogen Synthase Kinase 3β in Colorectal Cancer Progression
Minamoto, T., Nakada, M. K. M., Shimasaki, T., Motoo, Y., & Kawakami, K. (2012) · InTech eBooks · doi:10.5772/28036 · Cited by 2
Drugs that act on the immune system: cytokines and monoclonal antibodies
Spoerl, D., & Bircher, A. J. (2012) · Side effects of drugs annual · doi:10.1016/b978-0-444-59499-0.00037-4 · Cited by 2
Anti-EGFR Resistance in Colorectal Cancer: Current Knowledge and Future Perspectives
Boeckx, N., de Beeck, K. O., Deschoolmeester, V., Camp, G. V., Pauwels, P., & Peeters, M. (2014) · Current Colorectal Cancer Reports · doi:10.1007/s11888-014-0242-5 · Cited by 2
Molecular Pathology of Gastrointestinal Cancer
Yantiss, R. K., & Samowitz, W. S. (2012) · Surgical pathology clinics · doi:10.1016/j.path.2012.08.002 · Cited by 2
Panitumumab: An Arrow on Target
Kopper, L. (2010) · Pathology & Oncology Research · doi:10.1007/s12253-010-9257-7 · Cited by 2
BRAF, KRAS, and Phosphatidylinositol 3-Kinase in the Management of Metastatic Colorectal Cancer
Coutinho, A. K., Prolla, G., & Weschenfelder, R. F. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-012-0152-3 · Cited by 2
The Continuum of Care in Chemotherapy Approach to Metastatic Colorectal Cancer
Jenab-Wolcott, J., & Giantonio, B. J. (2013) · Current Colorectal Cancer Reports · doi:10.1007/s11888-013-0178-1 · Cited by 2
Optimal chemotherapy treatment for patients with advanced colorectal cancer
Stec, R., Bodnar, L., Smoter, M., Ma̧czewski, M., & Szczylik, C. A. (2011) · Współczesna Onkologia · doi:10.5114/wo.2011.20529 · Cited by 2
Anti-EGFR and Anti-VEGF Agents in First-Line Therapy for Advanced Colorectal Cancer
Mitchell, A. P., & Sanoff, H. K. (2017) · Current Colorectal Cancer Reports · doi:10.1007/s11888-017-0372-7 · Cited by 2
Curing patients with liver metastases from colorectal cancer
(2011) · Drug and Therapeutics Bulletin · doi:10.1136/dtb.2011.02.0022 · Cited by 2
Biologic Agents in the Treatment of Colorectal Cancer: The Last Decade; the Lost Decade?
Venook, A. P., & Saltz, L. B. (2013) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2013.33.e121 · Cited by 2
Recent advancements in immunotherapy for colorectal cancer
De, A., Kuppusamy, G., Bhuyan, N. R., Sauraj, & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13870-6.00011-8 · Cited by 2
Advances in targeted therapies for metastatic colorectal cancer
Pérez-García, J. M., Capdevila, J., Macarulla, T. M., Ramos, F. J., Élez, E., Ruiz-Echarri, M., & Tabernero, J. M. (2009) · Therapy · doi:10.2217/thy.09.11 · Cited by 2
Toward effective health technology regulation
Sorenson, C. (2015) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · Cited by 2
Regarding ‘Treatment of Colorectal Cancer with and without Bevacizumab: A Phase III Study’
Kabbinavar, F. F., & Kozloff, M. F. (2011) · Oncology · doi:10.1159/000327227 · Cited by 2
Metastasiertes kolorektales Karzinom – State of the Art 2011
Reinacher‐Schick, A. (2011) · Viszeralmedizin · doi:10.1159/000335089 · Cited by 2
Personalized Cancer Therapy Coming of Age: Clinical Highlights In 2009 and Future Directions
Ma, B. B. Y., & Loong, H. H.-F. (2010) · Personalized Medicine · doi:10.2217/pme.10.11 · Cited by 2
LOCALIZATION OF FOREIGN BODIES IN THE EYE.
Boardman, W. W., & Donovan, M. M. (1919) · PubMed · Cited by 2
Li, Y., Du, Y., Xue, C., Wu, P. J., Du, N., Zhu, G., Xu, H., & Zhu, Z. (2022) · Research Square · doi:10.21203/rs.3.rs-1529956/v1 · Cited by 2
Heymach, J. V., Zurita‐Saavedra, A., Kopetz, S., Cascone, T., Nilsson, M. B., & Guijarro, I. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm017.pub2 · Cited by 2
Present Situation and Prospect of Diagnosis and Treatment of Colorectal Cancer
Wang, J. (2016) · Springer eBooks · doi:10.1007/978-94-017-7755-1_1 · Cited by 1
Anti-vascular endothelial growth factor receptor in colorectal cancer: A review
Colombo, A., & Porretto, C. M. (2023) · International Journal of Gastrointestinal Intervention · doi:10.18528/ijgii230011 · Cited by 2
Saowapa, S., Polpichai, N., Tanariyakul, M., Wannaphut, C., Wattanachayakul, P., Danpanichkul, P., Suenghataiphorn, T., Kulthamrongsri, N., Siladech, P., & Tijani, L. (2024) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2024.2374161 · Cited by 1
Evaluating the treatment of metastatic colorectal cancer with monoclonal antibodies.
Popa, C., Ionescu, S. O., Mihăilă, D., Gal, I., Potecă, T. D., & Simion, S. (2012) · Europe PMC (PubMed Central) · Cited by 1
Senellart, H., Hiret, S., Guerin‐Meyer, V., & Bennouna, J. (2014) · Bulletin du Cancer · doi:10.1684/bdc.2014.1984 · Cited by 1
Strickler, J. H. (2012) · Translational gastrointestinal cancer · Cited by 1
Metastatic Colorectal Cancer: Optimizing Treatment with Anti-EGFR Monoclonal Antibody
Lam, K. O., & Lee, V. H.-F. (2012) · Journal of Cancer Therapy · doi:10.4236/jct.2012.326116 · Cited by 1
Carmona‐Bayonas, A. (2011) · Cancers · doi:10.3390/cancers3010945 · Cited by 1
Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies
Kumar, S. S., Price, T. J., Townsend, A. R., Hocking, C. M., & Hardingham, J. E. (2014) · Colorectal Cancer · doi:10.2217/crc.14.3 · Cited by 1
Evolving end points for clinical trials in advanced colorectal cancer
Gill, S., & Sargent, D. J. (2009) · Current Colorectal Cancer Reports · doi:10.1007/s11888-009-0020-y · Cited by 1
Panitumumab: leading to better overall survival in metastatic colorectal cancer?
Sebio, A., Stintzing, S., Stremitzer, S., Zhang, W., & Lenz, H. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.894502 · Cited by 1
Aktuelle medikamentöse Therapie des metastasierten Kolonkarzinoms
Folprecht, G. (2010) · Der Chirurg · doi:10.1007/s00104-010-1892-8 · Cited by 1
Wojtukiewicz, M. Z., Tokajuk, P., & Sierko, E. (2010) · Onkologia w Praktyce Klinicznej · Cited by 1
Optimising systemic therapy in metastatic colorectal cancer
Hui, E. P. (2013) · Hong Kong Journal of Radiology · Cited by 1
Biologic agents in the treatment of colorectal cancer: an update
Raj, N. P., & Saltz, L. B. (2014) · Colorectal Cancer · doi:10.2217/crc.14.26 · Cited by 1
Metadata
- Authors
- Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., Deeter, R., Shahin, S., & Amado, R. G.
- Affiliations
- Amgen (United States) (US)
- Venue
- Journal of Clinical Oncology
- Published
- 2009-02-10
- Volume
- 27
- Issue
- 5
- Pages
- 672-680
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2002226820
- Cited by
- 850
- References
- 30
- Citations by year
- 2026: 5 · 2025: 8 · 2024: 19 · 2023: 10 · 2022: 21 · 2021: 15 · 2020: 29 · 2019: 29 · 2018: 26 · 2017: 38 · 2016: 44 · 2015: 57 · 2014: 56 · 2013: 88 · 2012: 101
- FWCI
- 53.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amgen
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metastatic colorectal cancer, panitumumab, bevacizumab, oxaliplatin, irinotecan, EGFR inhibition, first-line chemotherapy, progression-free survival, treatment toxicity, KRAS mutation, anti-EGFR monoclonal antibody
- MeSH terms
- Bevacizumab, Irinotecan, Oxaliplatin, Panitumumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Organoplatinum Compounds, Colorectal Neoplasms, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
